XORTX plans Q4 2026 FDA IND filing for XRx — 026 gout trial using XORLO, targets USD 700 million U.S. market

XORTX outlined plans to submit an FDA IND in Q4 2026 for its XRx-026 gout program using XORLO. No new trial results were presented; the program is being advanced based on supportive prior results and FDA discussions. The planned XRX-OXY-102 study aims to support a future NDA by clarifying dosing behavior and clinical benefit. Management targets an NDA filing about one year after completing the study, subject to funding and execution. The company pegged the U.S. gout opportunity at more than USD 700 million in annual market potential. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. XORTX Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001171843-26-006109), on September 18, 2026, and is solely responsible for the information contained therein. (C) Copyright